Aside from, gene amplification and overexpression of HER2 can gain transforming opportunity by activating gene mutation in the kinase domain.In the event of pT2 pN0 a taxane based polychemotherapy moreover trastuzumab monotherapy is suggested which might be followed in the event of a HR+ tumor by neratinib monotherapy for nearly 1 12 months. For su